QQ客服 官方微博 反馈留言

	Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
	Sun, Yan; Cheng, Ying; Hao, Xuezhi; Wang, Jie; Hu, Chengping; Han, Baohui; Liu, Xiaoqing; Zhang, Li; Wan, Huiping; Xia, Zhongjun
	2016
卷号	16页码:265
关键词	Amrubicin Cisplatin Etoposide ED-SCLC Randomized clinical trial Chinese
ISSN号	1471-2407
DOI	10.1186/s12885-016-2301-6
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383008
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Sun, Yan,Cheng, Ying,Hao, Xuezhi,et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer[J],2016,16:265.
APA	Sun, Yan.,Cheng, Ying.,Hao, Xuezhi.,Wang, Jie.,Hu, Chengping.,...&Luo, Xiaoyan.(2016).Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.,16,265.
MLA	Sun, Yan,et al."Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer".16(2016):265.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。